NN8022-4241 In-market utilisation of liraglutide used for weight management in Europe: a retrospective medical record review study

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/35489
• EU PAS number:
  EUPAS16225
• Study ID:
  35489
• Official title and acronym:
  NN8022-4241 In-market utilisation of liraglutide used for weight management in Europe: a retrospective medical record review study
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Italy
• Study description:
  The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.
• Study status:
  Finalised

Research institutions and networks

Institutions

Novo Nordisk

Multiple centres: 50 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 25/02/2016

Actual: 25/02/2016

Study start date

Planned: 16/11/2016

Actual: 22/12/2016

Date of final study report

Planned: 31/05/2020

Actual: 04/10/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Novo Nordisk

Study protocol

Initial protocol

4241-protocol-redacted

Updated protocol

4241-protocol-version-8.0-eu-pas-reg-redacted

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

U1111-1185-3661 (WHO)